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Background: Chemokine receptors (CKRs), the primordial receptors for primate lentiviruses, are sufficient to
mediate virus-cell fusion. Several different fusogenic CKRs and related receptors provide a broad potential host cell
range, presumably advantageous for viral spread within a given infected individual, and across species. By contrast,
the additional constraint of obligatory CD4 binding, just prior to CKR engagement, radically restricts potential host
cells within an individual (or lymph node microenvironment), and might also limit xenotransmission, as CD4
sequences vary among primates. In spite of these potential drawbacks, CD4 dependent entry for SIV and HIV is the
rule rather than the exception, and is generally thought to have evolved by selection for 1) stabilization of virus–cell
surface interactions, and 2) conformational shielding of readily neutralized CKR binding epitopes. CD4 binding
residues of SIV and HIV envelope are recessed, (relatively hidden from immune detection) and may exhibit a strong
degree of automimicry, thus benefitting from self tolerance.
Documented evolution, within individual macaques, of neutralization-resistant CD4-dependent SIV, derived from
CD4-independent inocula, supports these ideas, but does not explain CD4’s exclusive role as the penultimate
receptor-even more striking, given the wide diversity of CKRs and other surface molecules that can serve as actual
fusion receptors for SIV. We, therefore, explored the additional, non-exclusive, hypothesis that surface CD4 on
leukocytes is a marker of a more favorable host cell environment, as compared to CD8, NK, or B cell surface
markers.
Results: We demonstrate progressive in vitro evolution of two SIV strains to CD4-dependence (and CXCR4 tropism)
in normal human PBMCs (hPBMCs). The two CD4-independent strains of SIV tested developed nearly complete CD4
dependence over several months of serial passage in hPBMCs, correlating with a limited number of non-
synonymous env region mutations, some previously reported to be determinants of CD4-dependency. The initial
ability of SIV stocks to grow to significant (albeit, relatively low) levels in CD4(−), CD14(−) cells was also lost with
long term passage. Rapid emergence and subsequent prominence of G!A and A!G mutations within env
regions associated with CD4 dependence was seen.
Conclusions: Progressive acquisition of strict CD4 tropism, independent of immunoselection, supports the idea that
surface CD4 identifies optimal host cells having intracellular environments most favorable to viral replication. The
prominence of mutations involving G to A, or A to G, suggests that APOBEC 3 mediated infidelity may facilitate
rapid switching of cell surface receptor usage within SIV swarms encountering fluctuating availability of optimal
CD4+CKR+ targets. These observations of non-immune selection are compatible with, and may accelerate,
simultaneous selection for previously described CD4-dependent neutralization resistance in vivo.
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SIV has crossed many primate species barriers during its
evolution to HIV [1,2], and the widely divergent outcomes
of infection (from benign subclinical to rapidly patho-
genic) reflect multiple host – virus interactions. Among
these are coreceptor usage [3,4], and cell subset tropism
withinprogressively colonizedmicroanatomicniches [5-7].
Lin et al. [8] have summarized the evidence that chemo-
kine receptors (CKRs) were the primordial lentivirus
receptors, with the evolution of penultimate CD4 binding
a more recent development in primate hosts. Most SIV
(and essentially all HIV) exhibit strong CD4 dependence,
which is generally thought to reflect the selective advan-
tage of high affinity CD4 binding for stabilization of cell-
virion interactions, and shielding of chemokine receptor
(CKR) binding sites from neutralizing antibodies [9,10].
Yet, with respect to stabilizing membrane interactions,
other cognate pairings (e.g., viral membrane ICAM – host
membrane LFA-1) stabilize cell-virus coupling during
retrovirus docking. Similarly, the explanation of CD4 de-
pendence as a means of protecting readily neutralized
fusogenic CKR binding epitopes begs the question: “Why,
despite fusogenic receptor diversity for SIV and HIV, has
CD4 emerged as the exclusive selecting co-receptor, rather
than functionally analogous CD8, or some ubiquitous sur-
face molecule (e.g., CD45)?” Our earlier demonstration
that CD4 co-caps with CKRs on the surface of gp120 or
virion exposed huPBMCs, and that blocking this capping
prevents infection [11] does not, by itself, explain why
CD4 should have eclipsed all other molecules in this role,
unless it were unique among surface molecules in its
actin-mediated association with CKRs. This would ap-
pear to be ruled out by work of Tardif and Tremblay
[12,13] demonstrating actin-mediated LFA-1 clustering,
post-HIV binding, and by observations from several la-
boratories (e.g., ref [14]) on the co-clustering of LFA-1,
CD8, and CKRs at the immunological synapse of CTLs.
CD4-independent SIV and HIV-2 strains can be sel-
ected in vitro [1,8,9,15,16], and isolated from the CNS of
macaques [17,18] and blood of rapid progressor (RP) or
late stage [10,19] animals – settings with a paucity of
CD4+ targets. Similarly, CD4 independent HIV-1 has
been recovered from the CNS of HIV+ individuals and
(very rarely) AIDS patients with extreme CD4+ cell de-
pletion, in some cases from CD8+ cells [20,21]. Of note,
Vodros et al., [3] demonstrated, within 12 days of infec-
tion, increased heterogeneity of circulating SIV envelopes
capable of mediating CD4-independent fusion in vitro.
They suggested that local depletion of CD4+ T cells avail-
able, within initially infected sites during the acute phase,
might select for CD4 independence.
Replacement of injected CD4-independent RP SIV by
CD4-dependent virus in macaques has been attributed
to neutralizing antibodies (Abs) arising roughly 40 weekspost infection,while (rare)persistenceofCD4-independent
SIV in RP animals was interpreted as the consequence of
feeble, ineffective, neutralizing Ab responses [10,19,22].
But RP macaques also have rapid loss of almost all sus-
ceptible CD4+ lymphocytes, so, likewise, non-immune
selective pressures favoring CD4 tropism would be ab-
sent, allowing persistent CD4-independence at the level
of non-immune selection, as well. Decreased fitness in
macaque PBMCs of CD4 independent SIV from rapid
progressors (vs. parental CD4-dependent virus) was con-
sidered in vitro artifact [10,22]. However, rapid progres-
sor (RP) SIV was not examined for in vitro evolution to
parental CD4 dependent phenotype and/or genotype dur-
ing maintenance in vitro. Referring to data not shown,
Vodros et al.[3] noted that “extensive passage on hPBMCs”
of a largely CD4-independent SIV strain “resulted in in-
oculum from which strictly CD4-dependent clones were
derived, suggesting that CD4-dependent viruses may be
more fit under these conditions.”
One previously unexplored potential pressure for the
selection of CD4 as the exclusive co-receptor for HIV is
that CD4 cells are intrinsically better internal hosts for
SIV (and HIV) replication than other primary cells, for
reasons (e.g., cell-type specific restriction factors) unre-
lated to surface CD4. This hypothesis predicts that,
among a swarm of SIV, CD4 dependent phenotypes will
out-compete strains with different (e.g. CD8 co-receptor)
or more promiscuous (e.g., CKR only) entry criteria, be-
cause they selectively infect host cells that are intrinsic-
ally more productive. This advantage should exist in the
absence of specific anti-SIV humoral or cell mediated
immunity, as long as there are sizable proportions of
both CD4+ and CD4(−) targets with suitable surface
CKRs for binding and fusion. Selection for CD4 depend-
ence might diminish in the face of drastically reduced
availability of activated CD4+ cells (as in RP macaques,
or macaque CNS infection, or within a “burned out”
node, depleted of in situ CD4+ activated T cells), or dur-
ing xenotransmission to a primate whose CD4 had much
lower avidity for envelope.
We set out to test the scenario of selection for CD4
tropism in the absence of immune pressure, by long
term culturing in normal hPBMCs of two SIV strains
which exhibit CD4 independence during initial rounds
of infection in hPBMCs [23,24].
Results
SIV stock strains are CD4 independent in hPBMCs, and
productively infect hPBMCs depleted of CD4+ and
CD14+ cells
SIV mac239 CEMx174 and 17E-Fr stocks, both produced
in CEMx174 cultures, were inoculated into wells con-
taining PHA stimulated hPBMCs. After continuous pas-
sage of SIV mac239 in CEM x 174 cells, the resulting
Iyengar and Schwartz Retrovirology 2012, 9:61 Page 3 of 11
http://www.retrovirology.com/content/9/1/61stock, which we here call SIV mac239 CEMx174, is CD4
independent for infection of human PBMCs, while
remaining CD4 dependent in macaque PBMCs, as previ-
ously reported [23,24]. This fortuitous observation gave
us a second SIV strain, along with SIV 17E-Fr (which
was genetically unchanged after passage in CEMx174
cells) to analyze for progressive acquisition of CD4 de-
pendence in hPBMCs. This phenotype was not due to
surface components incorporated from the CEMx174
line, in which case CD4 independence should have been
lost after just one round of replication in hPBMCs. Ra-
ther, sequencing of stock SIV mac239 CEMx174 indicates
the presence of several mutations differing from the par-
ental SIV mac239 [GenBank accession number M33262],
and previously associated with CD4 independence (dis-
cussed below).
Parallel cultures of equal numbers of anti-CD4 treated
hPBMCs, or PBMCs immunodepleted of CD4+ and
CD14+ cells, were established at the same time. Separate
experiments demonstrated comparable levels of day 5
proliferation, as measured by thymidine incorporation,
among these various cell populations (data not shown).
As shown in Figure 1A, anti-CD4 mAb treated hPBMCs
supported high replication (> 8,000 pg/ml p27) of both
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Figure 1 Stock vs. Passage 24 SIV CD4 dependence and infection of C
mac239 CEMx174 and SIV 17E-Fr in human PBMCs was robust (> 8,000 pg/m
concentrations of Leu3a. Limited supernatant volumes prevented endpoint
dilution. ImmunodepletedhPBMCs containing fewer than 1% CD4+ or CD1
at significantly lower levels (** p< 0.0001 vs. 8,000 pg/ml). B. By the 24th p
had lost the ability to infect PBMCs pretreated with anti-CD4. Moreover, no
line) in day 7 supernatants of hPBMC depleted of CD4+ and CD14+ cells.did untreated PBMCs. The Figure 1A supernatants were
not diluted to endpoint, but in similar experiments using
the stock viruses, anti-CD4 mAb treated cultures sup-
ported several fold higher levels of p27 production than
untreated control cultures, as determined by endpoint
dilution of day 7 or day 10 supernatants (Figures 2 and 3,
discussed below).
Lack of surface CD4 dependence for entry does not
formally prove that cells other than CD4+ lymphocytes
are actually being infected. CD4+ cells might still be se-
lectively targeted, via some non-CD4 mediated mechan-
ism. This point was addressed by documenting moderate
growth in hPBMCs rigorously depleted of CD4+ lympho-
cytes and CD14+ monocytes (< 1% CD4+, < 1% CD14+,
as determined by flow cytometric analysis), albeit with
significantly lower levels of virus production (~ 700 and
1100 pg/ml p27, respectively, of SIV mac239 CEMx174 and
17E-Fr, Figure 1A). The decreased growth of SIV in CD8
+ T cells, B cells, and other remaining CD4(−) CD14(−)
mononuclear cells, compared to anti-CD4 treated whole
PBMCs, suggests that, despite blocking and/or downre-
gulation of surface CD4, the CD4+ cells are still being
infected, and are producing more virus than the CD4(−)
cells from the same source. This is consistent with our
hypothesis of a selective growth advantage for virionsP24
B





D4+ and CD14+ depleted hPBMCs. A. Day 7 growth of stock SIV
l p27) whether or not cells were pretreated with CD4 blocking
dilutions, but contained p27 levels that remained off-scale (*) at 1:10
4+ cells still supported readily detectable levels of viral replication, but
assage in allogeneic hPBMCs, both SIV mac239CEMx174 and SIV 17E-Fr
growth of either strain was detectable above EIA sensitivity (dashed
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Switch to Exclusive CXCR4 Tropism 
BA
Anti-CD4 treated
Figure 2 Progressive changes in CD4 and CKR usage by SIV serially passaged in hPBMCs. A. Day 7 supernatant p27 concentrations of
hPBMC cultures, transiently treated with Leu3a anti-CD4 mAb during infection, were normalized to simultaneously mock-treated control cultures
(100%, dashed line --——). Initial 4- and 3-fold greater replication in Leu3a anti-CD4 mAb treated cultures of, respectively, SIV mac239 CEMx174
(abbreviated SIV mac239) and SIV 17E-Fr was followed by progressively increasing CD4 dependence during serial passage in unrelated human
donor PBMCs. B. By the 15th passage, when both SIV strains had become almost completely CD4 dependent (see A), CKR usage in both strains
had switched from roughly equal CXCR4 and CCR5 to nearly exclusive CXCR4 tropism, demonstrated by relative reduction of virus growth in cells
pretreated with blocking mAbs against CXCR4 vs. CCR5.
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even if surface CD4 is not utilized for entry. This level of
replication was absent in identically depleted cultures of
late passage, CD4 dependent, SIV, which produced only
uninfected control background levels of p27 (Figure 1B).
CD4 independent SIV passaged repeatedly in hPBMCs
becomes CD4 dependent in hPBMCs, exclusively CXCR4
tropic, and no longer infects hPBMCs depleted of CD4+
and CD14+ cells
The cultures established in hPBMCs (described above)
were re-fed weekly with fresh allogeneic PHA stimulated
normal hPBMCs and complete media. Table 1 shows
that significant percentages of the non-adherent CD4(−),
as well as CD4+ cells present in these cultures at days 1,
4, and 7 were positive for either CXCR4 or CCR5 (or
both). Moreover, the increasing ratio of CXCR4 : CCR5Figure 3 Different effects of soluble CD4 on SIV mac239 CEMX174 vs
(Leu3a, gray), enhanced infectivity of stock virus, but decreased growth of
17E-Fred, sCD4 appeared to have no effect on stock or P19 virus infectivity
day 7 for P19).expression during the 7 day culture period was not
markedly different for CD4+ vs. CD4(−) populations.
Aliquots of supernatant from SIV stocks (~103 TCID50)
or progressive weekly passages (P#) were sampled at 1–2
month intervals for sequencing, and used to infect nor-
mal PHA stimulated hPBMCs, with or without pre-
blocking by anti-CD4 mAb (samples from P0, P7, P15,
and P24), or anti-CKR mAb (samples from P0, P5, P13,
and P19), or pre-culture immunodepletion of CD4+,
CD14+ cells (P0 and P24). Additionally, P0 and P19 virus
samples were pre-incubated with soluble recombinant
CD4-IgG (sCD4) prior to inoculating PBMCs.
Surprisingly, initial stocks of SIV mac239 CEMx174 and
SIV 17E-Fr both actually grew better in hPBMCs transi-
ently blocked with Leu3a mAb during initial exposure,
than in unblocked controls. Nevertheless, during suc-
ceeding passages, CD4 independence was progressively. SIV 17E-Fred. A. For SIV 239CEMX174, sCD4 (striped), like anti-CD4
late passage virus, although to a lesser degree than Leu3a. B. For SIV
. (Note that P0 p27 values reflect day 10 culture supernatants vs.
Table 1 Percentage of CD4+ and CD4(−) non-adherent hPBMCs expressing receptors for SIV during one week cultures
Percentage of Cells Expressing Surface Markers
Surface markers: CD4(−)CXCR4+ CD4(−)CCR5+ CD4+CXCR4+ CD4+CCR5+
Day 1 37 22 47 8
Day 4 25 17 68 14
Day 7 53 7 36 4
Whole human PBMCs were stimulated with PHA+ IL-2, and maintained in complete medium (10% FCS) for one week, with sampling of resuspended cells on days
1, 4, and 7. Cells were dual stained with CD4 and CXCR4 or CCR5 specific mAbs, to determine the percentages of CD4+ and CD4(−) cells expressing CXCR4 or
CCR5 at various times. Because co-expression of CXCR4 and CCR5 on either CD4+ or CD4(−) cells was not determined, total percentages of CKR + cells are not
calculated by summing the four populations for each day.
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CXCR4 tropism (Figure 2B). Additionally, by passage 24,
both SIV strains had lost the ability to infect CD4(−),
CD14(−) huPBMCs (see Figure 1B).
SIV stock strains are not rendered less infectious by pre-
incubation with soluble IgG-CD4, and evolve discordant
sensitivities during hPBMC passage
As shown in Figure 3, results after pre-incubating SIV
with soluble IgG-CD4 were somewhat discordant for the
two viruses. For P0 SIV 239 CEMX174, sCD4 strongly
enhanced infection (as did the CD4 blocking mAbLeu
3a). For P19 SIV 239 CEMX174 isolates, which were al-
most totally blocked by Leu3a, sCD4 suppressed growth
by> 80%. Thus, with respect to SIV 239 CEMX174, sCD4
pre-incubation reduced infectivity generally comparable
to anti-CD4 mAb. However, in the case of SIV 17E Fred,
pre-incubation with sCD4 had no effect on CD4 inde-
pendent infectivity of stock strains or CD4-dependent
P19 isolates. Possible reasons for these observed differ-
ences are considered in the Discussion section.
Progressive emergence of variants with specific
mutations in the envelope region
We next asked whether there were any common muta-
tions emerging in the strains of SIV that had evolved
CD4 dependence (which can be conferred by single
mutations [25,26]) and, if so, how quickly they emerged.
We sequenced both strands of full length envelope from
15 clones, each, of stock SIV 17E-Fr and stock SIV
mac239 CEMx174 carried in CEMx174 cells, 15 clones
derived from hPBMC passage 7, and 15 clones from pas-
sage 24. Initial SIV mac239 CEMx174 virus, as well as the
neurotropic variant SIV 17E-Fr, contained residues (67
Met and 176 Asn) previously associated with CCR5
tropic, CD4 independent (in macaque cells) SIV recov-
ered from brains of macaques initially infected with WT
SIV mac239 [27].
Interestingly, both stock virus strains grown in
CEMx174 also retained certain key residues previously
associated with CD4 dependent infection in non-human
primates, including Met at position 165, Ile at 324, and
(in 17E-Fred only) Lys at 573,the CD4 contact point ofthe conserved C3 loop GGDPE region [16-18]. Thus, in
accordwithmostpublishedsequencesofCD4-independent
SIV grown in macaque PBMCs, our stock virus sequences
suggest stably exposed CKR binding sites as the basis
for initial CD4 independence in hPBMCs, rather than
complete loss of CD4 affinity.
Overall, the 15 clones of envelope from SIV 17E-Fr
stock virus were> 99.9% homologous at the amino acids
(aa) level with eachother and the published sequence of
this strain [28]. Despite the observed progressive acquisi-
tion of CD4-dependence, stock virus and all subse-
quently passaged 17E-Fr carried Gly at aa 751, a residue
previously shown to contribute to CD4 independence in
macaque astrocyte-tropic isolates [15]. For SIV mac239
CEMx174, all 15 stock clones were, again, remarkably
homogeneous, with> 99.9% aa homology among the 15
clones overall, and only two clones having more than a
single aa differing from this consensus sequence. Im-
portantly, none of this very limited heterogeneity
involved aa positions that subsequently underwent mu-
tation during passage in hPBMCs. Figure 4 aligns
regions of the starting nucleotide sequences of the two
stock strains (P0) with the predominant mutated
sequences, for the respective strains, recovered at P24.
For 17E-Fr, by passage 24, mutations in nucleotide
position 1148 (G to A) and 2222 (C to T) were present
in all 15 clones sequenced, leading to aa acid changes of
Gly to Glu, and Pro to Leu, at aa residues 383 (C3 do-
main), and 741 (proximal to the transmembrane do-
main), respectively (Figure 4A). An additional mutation
at nucleotide position 2326 (C to A) was seen in 12 of
15 clones from passage 24, yielding a Leu to Met conver-
sion at aa 776. Of these most common mutations, only
G to A at nucleotide position 1148 had appeared in 3 of
15 clones by passage 7, suggesting it may have been crit-
ical for the step-wise conversion to CD4-dependent
phenotype. Glu 813 Arg was present in 8 of 15 passage
24 clones, and several other substitutions were present
at frequencies of 4/15 or less.
The pattern of passage acquired mutations for SIV
mac239 CEMx174, was more complicated than for 17E-Fr,
with only a single mutation seen for the first time at pas-
sage 24, and not in stock or passage 7 samples
A.SIV 17E-Fred amino acid substitutions predominant in P24 Clones
Passage        region frequency
372 383
P0   C3 NTDKINLTAPRGGDPEVTFMW 
P24  NTDKINLTAPREGDPEVTFMW  15/15
730 741 750
P0  TM SYFQQTHIQQDPALPTREGKE        
P24  SYFQQTHIQQDLALPTREGKE   15/15 
766 776                 786  
P0  TM IEYIHFLIRQLIRLLTWLFSN           
P24 IEYIHFLIRQMIRLLTWLFSN   12/15
B.SIV mac239CEMx174 amino acid substitution predominant only  in P24 Clones 
Passage        region frequency
180 190          200 
P0 V2 KKEYNETWYSADLVCEQGNNT 
P24 KKEYNETWYSVDLVCEQGNNT     14/15 
C.SIV mac239CEMx174 amino acid substitutions present in P7 & P24 Clones 
Passage        region frequency
60 67            80 
P0 C1 DNGDYSEMALNVTESFDAWNN 
P7 DNGDYSEVALNVTESFDAWNN
P24 DNGDYSEVALNVTESFDAWNN     15/15 
 141   158 
P0 V1 ARVDMVNETSSCIAQDNCIGL
P7  AKVDMVNETSSCIAQDNCTGL    15/15  
P24 AKVDMVNETSSCIAQDNCTGL    15/15 
170 176 189 
P0  V2 FNMTGLNRDKKKEYNETWYS
P7   FNMTGLKRDKKKEYNETWYS    15/15 
P24 FNMTGLKRDKKKEYNETWYS    15/15 
   210 217       230 
P0  C2 HCNTSVIKESCDKHYWDAIRF 
P7 HCNTSVIQESCDKHYWDAIRF     15/15 
P24 HCNTSVIQESCDKHYWDAIRF     15/15 
300 310 320
P0  V3 ISLNKYYNLTIKCRRPGNKTV
P7 ISLNKYYNLTMKCRRPGNKTV   15/15 
P24 ISLNKYYNLTMKCRRPGNKTV   11/15 
330     335        341       350 
P0 V3 VFHSQRINDRPRQAWCWFGGK 
P7 VFHSQPINDRPKQAWCWFGGK   15/15 
P24 VFHSQPINDRPKQAWCWFGGK   15/15 
380  383 400
P0 C3 DGS---RRRSGSYLHVDKLQRRV
P7 DGSWRRRSGSYLHVDKLQRRV    15/15 
P24  DGSWRRRSGSYLHVDKLQRRV    15/15 
430 436 450
P0 C4 LRAMSYQTNNQHLA-SRQKCL
P7 LRAMSY--TNNQHLA-SRQKCL   15/15 
P24 LRAMSY--TNNQHLA-SRQKCL   14/15 
600 609 620
P0 TM VLKGPGAAEYLGMCV-TSLPH
P7 VLKGPGAAECLGMCV-TSLPH     15/15 
P24 VLKGPGAAECLGMCV-TSLPH     11/15 
620 631         640 
P0 TM HYCTMAXMQV-YQSGTMRLGK
P7    HYCTMAXMQV.HQSGTMRLGK       15/15 
P24   HYCTMAXMQV.HQSGTMRLGK       15/15 
   760 766 768         780 
P0 TM AVATAPGLDR--NIFIS-SAN-YA
P7  AVATAPGLGR--NIFIS-SAN-YA 766: 15/15     
P24 AVATAPGLGRYNIFIS-SAN-YA 766:  15/15,    768: 11/15 
   830 838      850 
P0  TM AISMRRSRSSGDLRQRLLRAR
P7   AISMRRSRPSGDLRQRLLRAR  15/15 
P24 AISMRRSRPSGDLRQRLLRAR  15/15 
Figure 4 (See legend on next page.)
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Figure 4 Predominant changes in amino acids between P0 and P7, or P24. Single letter sequences are shown for stock (P0), passage 7 (P7)
and/or passage 24 (P24) SIV clones, with the position of each change indicated in blue numbers above the P0 sequence, the P0 residue in red,
altered residues in green, and the clonal frequency of mutations indicated for passages. The variable (V), conserved (C), or transmembrane (TM)
regions in which mutations occur are indicated. SIV 17E-Fred (A) required few mutations to become CD4 dependent. By contrast, SIV
239CEMx174required multiple mutations by P24 (B) to become CD4 dependent, with many appearing by P7 and persisting through P24 (C).
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at nucleotide position 569, yielding Ala to Val at aa 190.
Unlike the SIV 17E-Fr findings, several additional non-
synonymous mutations were found to arise relatively
early (during or before passage 7) and persist through
passage 24, suggesting these changes also contributed to
early partial CD4 dependence and increased fitness
in vitro. The most consistent changes, seen in all fifteen
of the passage 7, and all fifteen of the passage 24 clones,
were: Met 67 Val, Arg 141 Lys, Ile 158 Thr, Asn 176 Lys,
Lys 217 Gln, Arg 335 Pro, Arg 341 Lys, 383 Trpinser-
tion, Tyr 631 His, Asp 766 Gly, Ser 838 Pro. Interest-
ingly, three of these changes were G to A and five were
A to G. Notably, almost every mutation emerging during
early (P7) hPBMC passage of SIVmac239CEMx174 and
persisting through P24, resulted in the restoration of an
aa present in the canonical SIVmac239 sequence. Add-
itionally, Ile 310 Met, and Tyr 609 Cys mutations were
seen in all 15 SIV mac239 CEMx174 clones at passage 7
(each reflecting an A to G mutation), but only in 11 of
15 clones at passage 24, with the other clones containing
the original stock virus residues. This could have been
due either to expansion (i.e., reemergence) of clones car-
rying the retained stock aa residues, or reverse mutation
back to initial sequences (via G to A mutation). As men-
tioned above, in every case, the emergent dominant
mutations present in P7 and P24 clones returned the se-
quence to the original published SIV mac239 residue, so
that P24 SIV mac239 CEMx174 was almost identical to the
canonical SIV mac239.
Discussion
An ability to replicate in the setting of severely limited
CD4+ targets (e.g., advanced disease or CNS infection)
would be a selective advantage for SIV or HIV at various
times in the course of a typical infection. CD4 independ-
ence might also facilitate xenotransmission to primate
species exhibiting dramatically lower binding constants
for viral envelope interaction with CD4 [29]. How often
this has occurred and to what extent species-specific
CD4 has been a barrier to xenotransmission remain un-
known. Despite the apparent advantages of CD4 in-
dependence, it is the exception rather than the rule,
suggesting a strong selective advantage for CD4 depen-
dent viruses.
Reacquisition of CD4-dependence has been observed for
neurotropic CD4-independent SIV injected peripherallyinto monkeys, and has been correlated with, and attribu-
ted to, development of neurotropic strain specific neu-
tralizing Abs. Here, we have presented the first evidence
that progressive reacquisition of CD4 dependence can
evolve in human cell cultures of SIV, over a similar
period of time, entirely independent of specific immun-
ity. These observations in no way contradict the import-
ance of immune selection for CD4 dependence in vivo,
but do suggest other components, such as cell type spe-
cific restriction factors, may exert selective pressure.
The possibility that rare residual CD4+ cells in CD4(−)
CD14(−) hPBMCs might be the source of detected initial
SIVstrain replication is exceedingly remote, as< 1% CD4+
cells scattered among non-infectable neighbors would be
unable to support the efficient cell-to-cell transmission
that accounts for> 95% of in vitro replication [30]. Also,
CD4+ cell contamination cannot explain why viral repli-
cation failed to reach detectable levels in identically
depleted cultures of late passage, CD4 dependent, SIV.
Figure 5 models a 9-fold selective advantage that
would be manifest after only three rounds of replication
for two hypothetical strains of virus—one CD4 inde-
pendent and capable of promiscuous entry into any
PBMC expressing appropriate surface CKR, the other
restricted to CD4+ cells bearing suitable surface CKR.
The model assumes identical efficiencies of entry for all
permissive combinations of virion and host cell, and
makes the further assumptions that CD4(−) and CD4+
lymphocyte targets are available at a ratio of roughly 2:
1, that encounters with targets are stochastically ran-
dom, and that the reproductive advantage of entering
CD4+ vs. CD4(−) cells is just 3-fold. In reality, the repro-
ductive advantage appears to be one or two orders of
magnitude greater, and hundreds of replication cycles
typically occur prior to detection of seropositivity. Under
such conditions, the chance of isolating CD4 independ-
ent strains from the peripheral circulation is small.
Up to four-fold increased infection of hPBMCs by
stock SIV in the presence of anti-CD4 mAb, seen in sev-
eral experiments (e.g., Figures 2 and 3), was probably
due to more efficient envelope binding of partially
capped, actin associated CKRs following Leu3a cross-
linking of CD4 [11]. Despite any such enhanced CKR
cell surface topography that might facilitate CD4-
independent viral infection of transiently Leu3a treated
cells, CD4 dependence increased progressively with suc-
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Figure 5 Modeling the selective advantage of strict CD4 dependence vs. promiscuous entry. The number of CD4 dependent (shaded) :
CD4 independent (unshaded) virions after 3 rounds of replication is 27:3. This illustrative hypothetical example makes the following simplifying
assumptions: CD4(−) and CD4+ potential host cells in a sufficiently activated state, and bearing the appropriate CKRs, are abundantly present in a
ratio of 2 : 1, yielding an encounter with CD4+ targets once in every three virus-cell interactions, on average (transient encounters of CD4
dependent virus with CD4(−) cells are shown only for the first round); the relative level of infectious virus released per infected CD4+ cell is 3x
that of an infected CD4(−) cell, and is the same for either strain of virus; the three types of permissive encounters between viruses and host cells
have equal efficiencies of entry.
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soluble Ig-CD4 are not readily apparent, but could relate
to one or both of the two established mechanisms for
sCD4 mediated inhibition of HIV: steric blocking of cel-
lular CD4 ligation, and induced envelope shedding from
virions [31]. In addition, the two strains of initially CD4-
independent SIV might show different initial CD4 bind-
ing affinities, and different degrees of change in affinities
during passage. Indeed, some envelopes have been found
not to bind multimeric sCD4 at all, perhaps due to tight
trimer packing, while certain glycosylation sites have
been found to confer relative resistance to sCD4 inhib-
ition [32]. Moreover, effects of sCD4 can include con-
centration dependent enhancement of infectivity, which
may vary with the presence or absence of surface CD4
expression of target cells [31,33-35]. Mono- and multi-
meric sCD4 were previously shown to enhance SIV
mac239 infectivity on CD4+ and CD4(−) CCR5+ cells
[31,33-35], presumably by stabilizing CKR binding sites
that are already partially exposed, and we suspect that
this mechanism is operative for our stock SIV mac239
CEMx174 as well. By passage 19, this enhancement was
replaced by predominant inhibition. The Leu3a blockingdata support the interpretation that exposure of cryptic
CKR binding sites in late passage isolates requires prior
engagement of CD4. In this context, either shedding of
envelope, or steric interference with envelope-CKR dock-
ing, could account for the suppressive effect of sCD4.
In contrast, the relative lack of effect of sCD4 co-
incubations on either initial or late passage SIV 17E-
Fred suggests that changes in CD4 binding affinity were
not involved in the acquisition of CD4 dependence. Ra-
ther, new conformational masking of CKR binding sites
may have evolved in the late-passage isolates, requiring
relatively prolonged contact with surface CD4 to allow
fusogenic binding. This observation is consistent with
the minimal binding of envelope to soluble CD4, as has
been previously described for some isolates, or binding
with only subtle changes in SIV env conformation, as
seen in recent cryo-electron studies [36]. Thus, mechan-
istic interpretation of discordant sCD4 effects is not
straightforward, but these experiments underscore the
fact that the structural/functional differences accumulat-
ing between initial and late passage SIV mac239 CEMx74
viruses were somewhat different in kind from those ac-
cumulating in SIV-17E-Fred.
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usage in hPBMCs to predominantly CXCR4 usage by
both strains has been described for SIV cultured in
hPBMCs [3], and may be functionally related to acquisi-
tion of CD4-dependence [25]. Lauren et al. [37] have
suggested the two are interrelated properties for SIVsm,
but this is not an absolute requirement. Which of the
envelope mutations associated in our experiments with
CD4 dependence determine CKR tropism is undefined.
The exact changes at aa positions 47 in the C1 domain,
and aa 316, 324, and 328 in the V3 loop, described by
Del Prete et al. [38] as conferring CXCR4 dependence
on SIV mac239 were not seen. However, mutations did
occur at nearby positions within the same regions (aa
positions 67, 334, 340), and may have played a similar
role in the context of the other mutations arising in SIV-
mac239 CEMx174 as it developed increasing CD4
dependence.
PHA/IL-2 stimulated PBMCs contain more CXCR4+
than CCR5+ expressing cells [39], and this difference is
more pronounced in CD4(+) vs. CD4(−) populations in
culture [Table 1], but relative abundance of CXCR4 vs.
CCR5 cannot be the sole reason for the tropism switch,
as both R5 tropic stock strains were grown in the
CEMx174 line that express ~ 20,000 CXCR4 surface
receptors per cell and no detectable surface CCR5. In
vivo switching of CCR5 tropic to CXCR4 tropic SHIV
has also recently been described in macaques, and is
correlated with enhanced, rather than de novo, binding
to CD4, based on a more open molecular conformation
that may facilitate heterotypic binding to CKRs [40].
The early appearance of G to A mutations in both SIV
mac239CEMx174 and 17E-Fr, along with the apparent
back and forth mutations between G and A seen with
SIV mac239 CEMx174 in the course of evolving binding
requirements, suggests a role for APOBEC 3 mediated G
to A mutations in rapidly generating optimal viral fitness
for growth in hPBMCs. This could help account for why
primate retroviruses have evolved only partial inhibition
of APOBEC 3 activity. It is interesting to note that, in all
but one instance, mutations acquired by SIVmac239-
CEMx174 restored the sequence to that of the canonical
SIV mac239.
Conclusions
Our findings suggest that in the absence of HIV specific
immunity, there are still strong selective pressures favor-
ing replication of SIV clones that limit their entry to
CD4+ cells. Seen in this light, surface CD4 becomes an
important “Welcome” sign for primate retroviruses, sig-
naling the most supportive host cells, rather than merely
an opportune foothold by which to gain entry. The
unique intracellular features of CD4+ T lymphocytes,
compared with minimally productive CD8+ T cells, NKcells, or B lymphocytes, accounting for such strong se-
lective pressure in vitro and in vivo remain unknown,
but may hold the key to future clinical interventions. Re-
cent studies have identified restriction factors for DCs
[41,42], and it is possible that these or other intracellular
factors limiting primate lentivirus replication will be
found in CD4(−) lymphocytes, as well.
Methods
Cells and reagents
The human CEMx174 cell line was originally obtained
from ATCC (Manassas, VA). Human PBMCs were sti-
mulated for 3 days with 5μg/ml of phytohemagglutinin
(PHA) and 2 U (IL-2) in 10% FCS RPMI 1640. CD4+ or
CD8+ cells were enriched by negative depletion using,
respectively, anti-CD8 or anti-CD4 magnetic beads, in
combination with anti-CD14 magnetic beads (Dynal,
Lake Success, N.Y.) at saturating concentrations. The
purity of T-cell subsets was determined for each subset
by flow cytometric analysis of cells immunostained with
20 μg/ml anti-CD4 and anti-CD8 monoclonal antibodies
(MAbs) detected with FITC-goat anti-mouse IgG. HIV
blocking anti-CD4 MAb Leu3A (BD Biosciences, San
Jose, CA, USA) was used at 10 μg/ml. Soluble CD4-IgG
(Progenics) was used at 10 μg/ml during 30 minute pre-
incubations with SIV, just prior to infection of cells.
Flow measurement of CKR expression on normal
hPBMCs stimulatedwith PHA+ IL-2 employed anti-CCR5
mAb 2D7 for flow cytometricstainining developed with
goat anti-mouse IgG-FITC; anti-CXCR4 mAb 12 G5 was
detected by flow cytometetry with goat anti-mouse IgG-
PE, In these experiments, anti-CD4 mAb was conjugated
to either FITC or PE, depending on the CKR mAb being
used.
This work was approved by the Institutional Review
Board of the Bloomberg School of Public Health, in con-
formance with the Helsinki Declaration on rights of
human subjects.
Virus infection
SIVmac239 and SIV17E-Fr [28], a kind gift from Dr. Jan-
ice Clements, were passaged in human derived
CEMx174 cells and purified from culture supernatants
by sucrose density gradient centrifugation. The resulting
SIV17E-Fr was essentially identical to the starting strain,
but the SIV mac239 derived stock virus was found to
differ in 15 of 15 clones from the published sequence of
SIVmac239 by three mutations previously associated with
CD4 independence. Thus, we refer to this CEMx174
stock strain throughout the text as SIV mac239CEMx174.
CEMx174 passaged stock viruses were serially pas-
saged in PHA+ IL-2 (2 IU) stimulated human PBMCs
obtained from normal control donors. Cultures were
refed with fresh medium twice weekly, and passaged into
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http://www.retrovirology.com/content/9/1/61fresh allogeneic human PBMCs every week. PHA+ IL-2
stimulated PBMCs were pretreated with Leu3A (or
mock treated) for 30 minutes on ice, and infected with
stock SIV (103 TCID50), or SIV from various passages
(culture supernatant containing ~ 5 ng/ml p27) for 2 hrs
at 37 °C. After infection, the cells were washed free of
virus x 2, and plated at 1x106 per well in quadruplicate
wells of a 48-well culture plate. Supernatants collected
on days 0, 3, 7 and 10 were assayed for p27 by enzyme
immunoassay (EIA, Coulter Immunology). Day 7 and/or
day 10 p27 values were used to assess relative rates of
growth among control and experimental groups. Groups
were statistically compared by two-way Student’s T- test.PCR amplification and sequencing of SIV env sequences
from cell culture supernatants
Genomic DNA was extracted from culture supernatants
of SIVmac239 CEMx174 and SIV 17E-Fr infected human
hPBMCs with QIA Amp DNA Blood mini Kit (Qiagen),
according to the manufacturer’s recommendations. Gen-
omic DNA was used for PCR amplification of the entire
SIV env gene in a hot start PCR (Taq Master Mix Kit,
Qiagen) according to manufacturer’s instructions in a
standard PCR buffer, and primers at a concentration of
0.5uM,P1 (5′GAGCAATCACGAAAGAGAAGAAGAAC-
3′) andP2 (5′CTGTCCCTGATTGTATTTCTGTCCC-3′)
for the first round and primers P3 (5′ GCTCTAGAATGG-
GATG TCTTGGGAATCAGCTGC-3′) and P4 (5′ CGGA-
TCCTCACAAGA GAGTGGCTCAAGCCC-3′) for the
second round, as previously described [43].
PCR products were run on a 0.7% low-melt agarose
gel, and the 2.6 kb env product was extracted and cloned
into the pCR2.1-TOPO vector (TOPO TA cloning kit,
Invitrogen) according to manufacturer’s instructions. Fif-
teen full-length env clones from each stock SIV virus,
passages 7 and 24 were randomly selected and sequenced
bi-directionally at the Johns Hopkins Sequencing Facility
using the M13F and M13R primers with the dye termin-
ator cycle sequencing method and 3730 DNA Analyzer
(Applied Biosystems). Sequence analysis was done using
SeqMan II, part of Lasergene v 4.03 (DNA Star Inc.).
Multiple sequence alignment was done using CLUSTAL
X with weighted residue weight table [44], built into the
MegAlign, part of Lasergene version 4.03 (DNA Star Inc.).Competing interests
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